News

Scientists from the Boston University School of Medicine (BUSM) believe they have found modifications in a new gene, PLXNA4, which may be a risk factor in Alzheimer’s Disease (AD) development. According to a recent article on Genetic Engineering News, researchers used data from a previous study, the…

Bioengineers at the University of Washington have designed peptide structures that can neutralize the conversion of a protein from its normal state into an abnormally folded, toxic form, preventing more than 40 amyloid diseases such as Alzheimer’s, Parkinson’s or Type 2 diabetes, for example. Ultimately, this could allow doctors…

A group of scientists is researching the possibility of utilizing a set of compounds developed for cancer treatment as a novel oral therapy for treating Alzheimer’s disease. Up until now, the team had only tested and evaluated injected epothilone D, a brain-penetrant MT-stabilizer, in mice and AD patients. However, in spite of the fact…

An abnormal protein in the brain may play an important role in the onset of Alzheimer’s disease, a group of scientists at the Mayo Clinic discovered. Although they still haven’t figured out whether this protein, called TAR DNA binding protein of 43kDa (TDP-43), is a cause of Alzheimer’s disease…

A drug prescribed for the treatment of arthritis is able to slow the progression of Alzheimer’s, according a study performed by researchers at the University of Southampton in the United Kingdom. Etanercept was administrated to patients with mild to moderate disease, and within a six-month period, the scientists verified that the…

As a result of new research conducted at the Mayo Clinic, patients with Alzheimer’s may all commonly share a newly discovered protein called TDP-43 as a potential cause for their disease, in addition to the well-known amyloid and tau proteins. Dr. Keith Josephs at the Mayo Clinic was the lead expert…